Genetics reveal why people respond differently to GLP-1 weight-loss drugs
New research links genetic variants in GLP1R and GIPR to differences in how patients respond to GLP-1 medications, pointing toward more personalized treatment.
GLP-1 drugs like semaglutide and tirzepatide have transformed weight-loss treatment for millions of people, but not everyone responds the same way. Some patients lose significant weight with minimal side effects, while others struggle with nausea or see only modest results. A new study published in Nature sheds light on why, pointing to genetic variants in two key receptor genes that may shape individual responses to these medications.
Details
The research focuses on two genes: GLP1R, which encodes the glucagon-like peptide-1 receptor, and GIPR, which encodes the glucose-dependent insulinotropic polypeptide receptor. Both of these receptors are direct targets of the GLP-1 class of medications, including semaglutide (the active ingredient in Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound), which acts on both GLP-1 and GIP receptors.
By analyzing genetic data from large patient populations, researchers identified specific variants in these genes that correlate with differences in drug efficacy and side-effect profiles. Some variants appear to make the GLP-1 receptor more or less sensitive to stimulation, which could explain why certain patients experience stronger appetite suppression and greater weight loss while others see a blunted response.
The GIPR gene variants are particularly relevant for dual-agonist drugs like tirzepatide, which target both the GLP-1 and GIP pathways. Variations in how the GIP receptor functions could influence whether a patient benefits more from a single-agonist or dual-agonist approach.
On the side-effect front, the study found that certain genetic profiles were associated with a higher likelihood of gastrointestinal symptoms, the most common complaint among GLP-1 drug users. Nausea, vomiting, and other GI issues are the leading reason patients discontinue treatment, so understanding who is most at risk could help clinicians make better prescribing decisions.
The findings build on a growing body of pharmacogenomic research, which examines how a person’s genetic makeup influences their response to specific drugs. While pharmacogenomics has already changed how doctors prescribe certain antidepressants and blood thinners, its application to GLP-1 medications is still in early stages.
Why It Matters
The GLP-1 drug market has exploded in recent years, with millions of prescriptions written annually for weight management and type 2 diabetes. But the one-size-fits-all approach to dosing and drug selection leaves a lot of room for improvement. Patients often go through weeks or months of dose titration and trial-and-error before finding what works for them, and some give up entirely because of intolerable side effects.
If genetic testing could identify ahead of time which patients are likely to respond well to semaglutide versus tirzepatide, or who might need a different dosing strategy, it could save time, money, and frustration. It could also reduce unnecessary medication switches and improve long-term adherence, which remains one of the biggest challenges with GLP-1 therapy.
For the peptide community more broadly, this research underscores something that experienced users already know: individual biology matters. Two people can take the same compound at the same dose and have very different outcomes. Genetics is one piece of that puzzle, alongside factors like metabolic health, diet, activity level, and gut microbiome composition.
This kind of precision medicine approach could also influence how newer compounds in the pipeline, including triple-agonist drugs like retatrutide, are prescribed and studied. If receptor genetics play a meaningful role in outcomes, clinical trials may need to account for these variants when evaluating efficacy.
What’s Next
The researchers noted that while the genetic associations are statistically significant, translating them into clinical tools will take time. Developing a validated genetic test that doctors can order before prescribing a GLP-1 drug is still likely years away. Larger, more diverse patient studies will be needed to confirm the findings across different populations and ethnic groups.
In the near term, the results may influence how pharmaceutical companies design their clinical trials for next-generation obesity drugs. Stratifying trial participants by GLP1R and GIPR genotype could reveal subgroup differences that might otherwise be masked in aggregate data.
Several companies are already exploring companion diagnostics for GLP-1 therapies, and this research adds momentum to those efforts. The broader trend toward personalized medicine in metabolic health is picking up speed, and genetic profiling may eventually become a routine part of the prescribing process for weight-loss medications.
For now, the practical takeaway is straightforward: if a GLP-1 drug isn’t working as expected, genetics could be part of the reason. As the science matures, patients and clinicians will have better tools to match the right drug to the right person from the start.
Related Reading
Original Source
nature.com →